Incyte Corporation (INCY)
NASDAQ·Healthcare·Biotechnology
$96.99
+1.33%
Mkt Cap $19.15B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 10, 2026 | $1.35B | $1.51B | +11.22% | $1.90 | $1.80 | -5.26% | — | — |
| Q4 2025 Oct 28, 2025 | $1.35B | $1.37B | +0.87% | $1.66 | $2.26 | +36.14% | — | — |
| Q3 2025 Jul 29, 2025 | $1.26B | $1.22B | -3.29% | $1.39 | $1.57 | +12.95% | — | — |
| Q2 2025 Apr 29, 2025 | $1.15B | $1.05B | -8.68% | $1.01 | $1.16 | +14.85% | — | — |
| Q1 2025 Feb 10, 2025 | $1.00B | $1.18B | +17.30% | $1.57 | $1.43 | -8.92% | — | — |
| Q4 2024 Oct 29, 2024 | $1.14B | $1.14B | -0.51% | $1.12 | $1.07 | -4.46% | — | — |
| Q3 2024 Jul 30, 2024 | $1.03B | $1.04B | +1.77% | $0.78 | -$1.82 | -333.33% | — | — |
| Q2 2024 Apr 30, 2024 | $921.89M | $880.89M | -4.45% | $0.84 | $0.64 | -23.81% | — | — |
| Q1 2024 Feb 13, 2024 | $1.00B | $1.01B | +1.12% | $1.16 | $1.06 | -8.62% | — | — |
| Q4 2023 Oct 31, 2023 | $966.90M | $919.02M | -4.95% | $1.09 | $1.10 | +0.92% | — | — |
| Q3 2023 Aug 1, 2023 | $910.25M | $954.61M | +4.87% | $0.83 | $0.99 | +19.28% | — | — |
| Q2 2023 May 2, 2023 | $857.52M | $808.67M | -5.70% | $0.85 | $0.37 | -56.47% | — | — |
| Q1 2023 Feb 7, 2023 | $878.25M | $926.70M | +5.52% | $0.59 | $0.62 | +5.08% | — | — |
| Q4 2022 Nov 1, 2022 | $842.66M | $823.30M | -2.30% | $0.72 | $0.60 | -16.67% | — | — |
| Q3 2022 Aug 2, 2022 | $818.49M | $911.40M | +11.35% | $0.79 | $1.01 | +27.85% | — | — |
| Q2 2022 May 3, 2022 | $749.98M | $733.24M | -2.23% | $0.57 | $0.55 | -3.51% | — | — |
| Q1 2022 Feb 8, 2022 | $812.44M | $862.85M | +6.20% | $0.84 | $0.10 | -88.10% | — | — |
| Q4 2021 Nov 2, 2021 | $548.77M | $812.99M | +48.15% | $0.76 | $1.18 | +55.26% | — | — |
| Q3 2021 Aug 3, 2021 | $685.88M | $705.71M | +2.89% | $0.74 | $0.80 | +8.11% | — | — |
| Q2 2021 May 4, 2021 | $656.80M | $604.72M | -7.93% | $0.65 | $0.67 | +3.08% | — | — |